Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-10
2007-07-10
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S359100
Reexamination Certificate
active
11315753
ABSTRACT:
The present invention relates to certain fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor.Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, DP receptor antagonists, and the like.
REFERENCES:
patent: 2006/0167270 (2006-07-01), Semple et al.
patent: 10148617 (2003-04-01), None
patent: 0529854 (1993-03-01), None
patent: 1305286 (2004-12-01), None
patent: WO 0166520 (2001-09-01), None
patent: WO 0179169 (2001-10-01), None
patent: WO 02094830 (2002-11-01), None
patent: WO 03002582 (2003-01-01), None
patent: WO 03022814 (2003-03-01), None
patent: WO 03062200 (2003-07-01), None
patent: WO 03078409 (2003-09-01), None
patent: 2004032928 (2004-04-01), None
patent: 2004033431 (2004-04-01), None
patent: 2004103370 (2004-12-01), None
patent: WO 2005011677 (2005-02-01), None
patent: WO 2005016867 (2005-02-01), None
patent: WO 2005016870 (2005-02-01), None
patent: WO 2005044816 (2005-05-01), None
patent: WO 2005077950 (2005-08-01), None
Alterman, M. et al., “Fast microwave-assisted preparation of aryl and vinyl nitriles and the corresponding tetrazoles from organo-halides”, J. Org. Chem. 65:7984-89 (2000)(supporting information attached).
Bays, H. et al., “Pharmacotherapy for Dyslipidaemia—Current therapies and future agents”, Expert Opinion on Pharmacotherapy, Ashley, London, GB, vol. 4(11):1901-38 (2003).
Cahn, R.S. et al., “Specification of molecular chirality”, Angew. Chem. Internat. Edit. 5(4):385-415 (1966).
Chang, A. Y. et al., “Ciglitazone, a new hypoglycemic agent”, Diabetes 32:830-38 (1983).
Clayton, S. et al., “A total synthesis of (±)-epibatidine”, Tetrahedron Letters 34(46):7493-6 (1993).
Cohen, T. et al., “Synthetically useful β-lithioalkoxides from reductive lithiation of epoxides by aromatic radical anions”, J. Org. Chem. 55:1528-36 (1990).
Coleman, D.L., “Fat(fat) and Tubby (tub): Two autosomal recessive mutations causing obesity syndromes in the mouse”, Journal of Heredity 81:424-7 (1990).
Coleman, Douglas L., “Diabetes-obesity syndromes in mice”, Diabetes 31:1-6 (1982).
Collier, T. L. et al., “Radiosynthesis and in-vivo evaluation of the psuedopeptide s-opioid antagonist”, J. Labelled Cpd. Radiopharm. 42(1):S264-6 (1999).
Cornhill, J. Frederick et al., “Topographic study of sudanophilic lesions in cholesterol-fed minipigs by image analysis”, Arteriosclerosis Thrombosis, and Vascular Biology 5(5):415-426 (1985).
Corsaro, A. et al., “Steric course of some cyclopropanation reactions of L-threo-hex-4-enopyranosides”, Tetrahedron Letters 60:3787-95 (2004).
Delporte, Marie-Laure et al., “Pre- and post-translational negative effect of β-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies”, Biochem. J. 367:677-85 (2002).
Effenberger, F. et al., “Regioselective halo- and carbodesilylation of (trimethylsilyl)-1- methylpyrazoles”, J. Org. Chem. 49:4687-95 (1984).
Eriksson et al., “Increased incidence of congenital malformations in the offspring of diabetic rats and their prevention by maternal insulin therapy”, Diabetes 31:1-6 (1982).
Flechtner-Mors, M. et al., “Effects of acipimox on the lipolysis rate in subcutaneous adipose tissue of obese subjects”, Diabetes Metab Res Rev 17:387-90 (2001).
Friedman, J. et al., “Tackling a weighty problem”, Cell 69:217-20 (1992).
Gerrity, R. et al., “Diabetes-induced accelerated atherosclerosis in swine”, Diabetes 50:1654-65 (2001).
Guyton, John R., “Effect of Niacin on Atherosclerotic Cardiovascular Disease”, Am J Cardiol, 82:18U-23U (1998).
Haddach, A. et al., “An efficient method for the N-debenzylation of aromatic heterocycles”, Tetrahedron Letters 43:399-402 (2002).
Hodgson, D. et al., “Intramolecular cyclopropanation of unsaturated terminal epoxides”, J. Am. Chem. Soc. 126:8664-5 (2004).
Hodgson, D., “Intramolecular cyclopropanation of unsaturated terminal epoxides”, JACS 126:8664-5 (2004)(supporting information attached).
Hodson, et al., J. Am. Chem. Soc. 126:8664 (2004).
Holland, G. et al., “Heterocyclic tetrazoles, a new class of lipolysis inhibitors”, J. Med. Chem. 10:149-54 (1967).
Horinoshi, H. et al., “Troglitazone (CS-045), a new antidiabetic drug”, Ann. Rep. Sankyo Res. Lab. 46:1-57 (1994).
Katritzky, A. et al., “Alpha-lithiation of N-alkyl groups in pyrazoles”, Tetrahedron Letters 39:2023-9 (1983).
Koranyi, L. et al., “Glucose transporter levels in spontaneously obese (db/db) insulin-resistant mice”, J. Clin. Invest. 85:962-7 (1990).
Krynitsky, J. et al., “2-ethylhexanonitrile”, Org. Synth. Coll. vol. 4 p. 436 (1963); vol. 32 p. 65 (1952).
Latli, B. et al., “Novel and potent 6-chloro-3-pyridinyl ligands for the α4β2 neuronal nicotinic acetylcholine receptor”, J. Med. Chem. 42:2227-34 (1999).
Latli, B. et al., “Supporting information for ”Novel and potent 6-chloro-3-pyridinyl ligands for the α4β2 neuronal nicotinic acetylcholine receptor, J. Med. Chem. pp. 2227(1999).
Le Bas, M-D et al., “Radioiodinated analogs of EP 00652218 for the exploration of the tachykinin nk1 receptor by spect”, J. Labelled Cpd. Radiopharm. 44(1):S280-2 (2001).
Lorenzen, A. et al., “Characterization of a g protein-coupled receptor for nicotinic acid”, Mol. Pharmacol. 59(2):349-57 (2001).
Lorenzen, A. et al., “G protein-coupled receptor for nicotinic acid in mouse macrophages”, Biochem. Pharm. 64:645-48 (2002).
Mariano, P. et al., “Mechanistic aspcts of gas-phase photodecarbonylation reactions of bicycle[3.1.0]hexanones”, J. Org. Chem. 45:1753-62 (1980).
Matsuda, M. et al., “Role of adiponectin in preventing vascular stenosis”, J. Biol. Chem. 277(40):37487-91 (2002).
Miller, R.D. et al., “Deoxygenation of sulfoxides promoted by electrophilic silicon reagents: preparation of aryl-substituted sulfonium salts”, J. Org. Chem. 53:5571-3 (1988).
Movassaghi, M. et al., “A direct method for the conversion of terminal epoxides into γ-butanolides”, J. Am. Chem. Soc. 124(11):2456-7 (2002).
Newman-Evans, R. et al., “The influence of intramolecular dynamics on branching ratios in thermal rearrangements”, J. Org. Chem. 55:695-711 (1990).
Nishimura, J. et al., “A novel synthesis of methylcyclopropanes”, Tetrahedron Letters 25:2647-59 (1969).
Olivo, H. et al., “Synthetic studies on the trans-Chlorocyclopropane dienyne side chain of Callipeltoside-A”, Org. Lett. 2(25):4055-8 (2000)(supporting information attached).
Prelog, V. et al., “Basic principles of the CIP-system and proposals for a revision”, Angew. Chem. Int. Ed. Engl. 21:567-83 (1982).
Royo, T. et al., “Effect of gemfibrozil on peripheral atherosclerosis and platelet activation in a pig model of hyperlipidemia”, European Jour. Of Clinical Invest. 30:843-52 (2000).
Schaus, S. et al., “Highly selective hydrolytic kinetic resolution of
Boatman P. Douglas
Jung Jae-Kyu
Schrader Thomas O.
Semple Graeme
Skinner Philip J.
Arena Pharmaceuticals Inc.
Barker Michael P.
McKane Joseph K.
Spruce Lyle W.
LandOfFree
Fused pyrazole derivatives and methods of treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused pyrazole derivatives and methods of treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused pyrazole derivatives and methods of treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3799551